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After infecting peripheral sites, herpes simplex virus
(HSV) invades the nervous system and initiates latent
infection in sensory neurons. Establishment and
maintenance of HSV latency require host survival,
and entail repression of productive cycle (‘‘lytic’’)
viral gene expression. We find that a neuron-specific
microRNA, miR-138, represses expression of ICP0, a
viral transactivator of lytic gene expression. Amutant
HSV-1 (M138) with disrupted miR-138 target sites in
ICP0 mRNA exhibits enhanced expression of ICP0
and other lytic proteins in infected neuronal cells
in culture. Following corneal inoculation, M138-
infected mice have higher levels of ICP0 and lytic
transcripts in trigeminal ganglia during establish-
ment of latency, and exhibit increased mortality and
encephalitis symptoms. After full establishment of
latency, the fraction of trigeminal ganglia harboring
detectable lytic transcripts is greater in M138-
infected mice. Thus, miR-138 is a neuronal factor
that represses HSV-1 lytic gene expression, promot-
ing host survival and viral latency.
INTRODUCTION
Herpes simplex viruses 1 and 2 (HSV-1 and HSV-2) cause a
variety of diseases ranging from common cold sores to rare
but fatal brain diseases such as encephalitis. HSV alternates
between two distinct infection programs, productive (‘‘lytic’’)
infection and latent infection. During lytic infection, infectious
virus is abundantly produced and many viral genes are highly
expressed. Immediate-early (IE) genes are expressed first and
activate the expression of subsequently expressed early (E)
and late (L) genes. Among the IE gene products is ICP0, which
acts as a promiscuous transactivator of genes introduced by
transfection or infection and is required for efficient lytic infection
in many cell types (Cai and Schaffer, 1992; Chen and Silverstein,
1992). ICP0 is a RING finger E3 ubiquitin ligase (Boutell et al.,
2002) that promotes degradation and dispersal of proteins that446 Cell Host & Microbe 15, 446–456, April 9, 2014 ª2014 Elsevier Inmediate intrinsic antiviral resistance (reviewed in Boutell and
Everett, 2013). It antagonizes chromatin-mediated silencing
(Cliffe and Knipe, 2008; Ferenczy and DeLuca, 2009, 2011; Gu
et al., 2005; Gu and Roizman, 2007; Kalamvoki and Roizman,
2010) and also antagonizes innate immunity by interfering with
signaling from pattern recognition receptors that leads to inter-
feron production (Melroe et al., 2004; Mossman et al., 2000;
Orzalli et al., 2012; Paladino et al., 2010).
Following inoculation and lytic infection at a peripheral site on
a mammalian host, HSV gains entry to axons of sensory neurons
and is transported back to cell bodies in sensory ganglia. The
virus initiates lytic infection of the ganglia (acute ganglionic repli-
cation) but also begins the process of establishing latent infec-
tion in sensory neurons. HSV latency entails survival of the
host in the face of the ability of the virus to invade the central
nervous system (CNS) and cause lethal encephalitis. During
latent infection no infectious virus is detected and lytic gene
expression is strongly repressed, although low levels of lytic
transcripts can be found using sensitive PCR-based assays
(Chen et al., 2002; Giordani et al., 2008; Kramer et al., 1998;
Kramer and Coen, 1995; Pesola et al., 2005; Tal-Singer et al.,
1997). The only abundantly expressed gene products arise
from the latency-associated transcripts (LAT) locus (Rock
et al., 1987; Stevens et al., 1987). This locus is important for re-
pressing lytic gene expression during establishment andmainte-
nance of latency in a mouse model (Chen et al., 1997; Garber
et al., 1997). Host factors (reviewed in Roizman et al., 2013),
including elements of innate and acquired immunity (e.g., Knick-
elbein et al., 2008; Luker et al., 2003), and the neuronal milieu
(e.g., Hafezi et al., 2012; Kolb and Kristie, 2008; Yordy et al.,
2012) are also thought to contribute to repression of lytic gene
expression, survival, and latency. However, the underlying
mechanisms are still largely undefined.
MicroRNAs (miRNAs) are 22 nucleotide-long noncoding
RNAs that target mRNA sequences, particularly those comple-
mentary to nucleotides 2–8 (seed region) of the miRNA. miRNAs
are incorporated into the RNA-induced silencing complex
(RISC), which guides the recruitment of the target mRNA for
degradation and/or translational repression (reviewed in Car-
thew and Sontheimer, 2009). miRNAs regulate many cellular
and developmental processes, and changes in their levels
are associated with human diseases including virus infections
(reviewed in Cullen, 2011; Mendell and Olson, 2012). Notably,c.
Figure 1. Neuron-Specific miR-138 Can
Target HSV ICP0
(A) qRT-PCR analysis. miR-138 copy numbers
normalized to amounts of total RNA in the various
tissues and cells indicated below the graph.
Neuro-2A + HSV-1; moi = 50, and 16 hpi. Assays
were performed in triplicate with standard de-
viations shown as error bars.
(B) Schematic diagram showing candidate
miR-138 target sites in the 30 UTRs of HSV-1
and HSV-2 ICP0 mRNAs. White boxes indi-
cate the coding sequences. Candidate miR-
138 target sites are shown in hatched and gray
boxes.
(C) Sequences of candidate miR-138 target
sites. Below each candidate target site is the
sequence of miR-138 (conserved in mouse,
rat, monkey, and human). Underlined are
miR-138 seed sequences. Solid and dashed
vertical lines signify Watson-Crick and G-U
wobble base pairs, respectively. Arrows point
to nucleotide substitutions in mutant forms of
target sites and miR-138 with altered bases in
italics.
(D) miR-138 mimic reduces ICP0 mRNA
and protein levels. 293T cells were cotransfected
with miR-138 or miR-M138 mimics and an
ICP0 WT plasmid. Left, ICP0 mRNA levels
normalized to the levels of human GAPDH as
measured by qRT-PCR in triplicate. The error bar indicates the standard deviation. Right, ICP0 protein levels analyzed by western blot in the upper panel and
actin in the lower panel as a loading control.
(E) miR-138 expressed from an expression plasmid downregulates ICP0 protein expression. 293T cells were mock transfected or cotransfected with pcDNA-
miR-138 plasmid, a WT or M138 ICP0 expression plasmid, and a GFP expression plasmid (control), as indicated above the images. ICP0 (top panel) and GFP
(bottom panel) protein levels were assessed using western blots.
Cell Host & Microbe
Host miRNA Promotes HSV-1 Latencythe LAT locus encodes several miRNAs (Flores et al., 2013; Jurak
et al., 2010; Tang et al., 2008, 2009; Umbach et al., 2008), which
are differentially expressed during acute infection and latent
infection (Kramer et al., 2011; Tang et al., 2008; Umbach et al.,
2008) and have been hypothesized to play a role in repressing
lytic gene expression. Some host miRNAs have also been sug-
gested to play a role in HSV infection (Hill et al., 2009; Mulik
et al., 2012; Zheng et al., 2011). However, repression of HSV
gene expression by host miRNAs has not been demonstrated.
Because HSV latent infection occurs in neurons, wewondered
whether a neuron-specific miRNA might repress lytic gene
expression. In a previous deep sequencing study of miRNAs
expressed during latency in mice (Umbach et al., 2008), we
noticed that reads of miR-138 were highly represented in trigem-
inal ganglia (TG). Earlier studies had found abundant expression
of miR-138 in brain or neuroblastoma cell lines relative to other
tissues or cell lines (Landgraf et al., 2007; Obernosterer et al.,
2006). This miRNA was later found to regulate dendritic spine
morphogenesis in the mouse brain by modulating APT1 (Bane-
rjee et al., 2009; Siegel et al., 2009), and its expression in mouse
sensory ganglia was reduced when the gene encoding the
miRNA-processing enzyme Dicer was disabled in a subset of
sensory neurons (Zhao et al., 2010).
The neuronal expression of miR-138 prompted us to search
HSV-1 and HSV-2 genomes for complementary sequences,
and we identified ICP0 mRNA as a potential target. Notably,
ICP0 is required for efficient acute ganglionic replication and
reactivation from latency (Cai et al., 1993; Halford and Schaffer,Cell2001; Leib et al., 1989; Thompson and Sawtell, 2006). We
hypothesized that miR-138 might repress ICP0 and thereby lytic
gene expression in neurons, thus facilitating latency. Here we
show that miR-138 directly downregulates ICP0 and lytic gene
expression in cell culture. Moreover, mutating miR-138 target
sites in ICP0 mRNA enhances lytic viral gene expression in
neuronal cells in culture and in TG, and makes the virus more
virulent in a mouse model. Therefore, we identify a neuronal
factor that promotes HSV-1 latency by directly targeting a viral
gene.
RESULTS
Neuron-Specific miR-138 Can Repress ICP0 Expression
To investigate the neuronal specificity of miR-138 expression,
we quantified miR-138 in mouse brain, mouse trigeminal
ganglion (TG), primary neurons from rat superior cervical
ganglion (SCG), and four different cultured cells, neuronal
Neuro-2A cells (from mouse brain), and nonneuronal cells,
293T, Vero, and human foreskin fibroblast (HFF) using stem-
loop qRT-PCR. miR-138 levels in mouse brain and TG, rat
SCG neurons, and Neuro-2A cells were much higher than those
in Vero, 293T, and HFF cells, and levels of miR-138 in Neuro-2A
cells remained high following infection by HSV-1 (Figure 1A).
These data quantitatively confirm that miR-138 is enriched in
neuronal tissues and cells.
Sequence alignments revealed that the seed region of miR-
138 is completely complementary to two potential target sitesHost & Microbe 15, 446–456, April 9, 2014 ª2014 Elsevier Inc. 447
Figure 2. Binding of miR-138 to ICP0mRNA
At the top is a schematic diagram of the HSV-1
genome with long (UL) and short (US) unique
sequences indicated and long (TRL and IRL) and
short (IRS and TRS) repeat sequences shown in
hatched boxes. Below is an expanded view of the
ICP0 gene with the transcription start site indi-
cated as a black dot, introns as zigzags, and the
candidate target sites of miR-138 andHSV-1miR-
H2 as arrows. The two bottom panels show
aligned Illumina sequence reads from control
(upper) andmiR-138 transduced (lower) 293 cells.
Each point represents a cluster of reads starting
at the same 50 start site. The vertical lines in
these panels indicate the positions of the candi-
date miR-138 and miR-H2 binding sites. See also
Figure S1.
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Host miRNA Promotes HSV-1 Latencyin the 30 untranslated region (UTR) of HSV-1 ICP0mRNA (Figures
1B and 1C) and to one potential target site in the 30 UTR of HSV-2
ICP0 mRNA. One of the sites in HSV-1 also shows high overall
complementarity with miR-138 (Figure 1C). To test whether
miR-138 can repress ICP0 expression, we transfected a miR-
138 mimic or a variant mimic bearing three nucleotide changes
in the seed region (miR-M138; Figure 1C) together with an
ICP0 expression plasmid. The miR-138 mimic resulted in
reduced ICP0 protein and mRNA expression relative to the
variant mimic (Figure 1D). In a second cotransfection experi-
ment, miR-138 expressed from a plasmid downregulated ICP0
expressed from a plasmid encoding a wild-type (WT) 30 UTR,
but not from one (ICP0M138) containing three nucleotide substi-
tutions at each binding site of the miR-138 seed region (Figures
1C and 1E). Taken together, these results show thatmiR-138 can
repress ICP0 expression through its target sites in ICP0mRNA in
a seed region-dependent manner.
Identification of miR-138 Target Sites by PAR-CLIP
To investigate whether miR-138 binds to its candidate target
sites on ICP0 mRNA in HSV-infected cells, we performed a
photoactivatable ribonucleoside-enhanced crosslinking and
immunoprecipitation (PAR-CLIP) experiment, in which mRNAs
were labeled with 4-thiouridine, UV-crosslinked to RISCs, immu-
noprecipitated using an antibody against Argonaute (Ago)
proteins, treated with RNase T1, and converted to cDNA for
deep sequencing analysis. 293 cells were stably transduced
either with a control vector or a miR-138 expression vector.
miR-138 transduced cells expressed 7-fold higher levels of
miR-138 than did control transduced cells (see Figure S1A avail-
able online). They also exhibited stronger downregulation of
reporter gene expression from a plasmid containing either two
perfect miR-138 target sequences or the ICP0 30 UTR sequence
in the 30 UTR of the reporter gene than did the control transduced448 Cell Host & Microbe 15, 446–456, April 9, 2014 ª2014 Elsevier Inc.cells (Figure S1B). Both the control
and the miR-138 transduced cells were
infected with HSV-1 and subjected to
PAR-CLIP. While cells transduced with
both vectors showed clusters of reads
of ICP0 mRNA at sites complementary
to HSV-1 miR-H2, as previously ob-served (Flores et al., 2013), only cells transduced with miR-138
showed clusters of reads aligned to the two predicted miR-138
target sites (sites 1 and 2; Figures 1B, 1C, and 2). The clusters
in site 1 showed many more reads than those in site 2, which
could be due to the lack of a U in site 2, or the lower overall
complementarity of site 2 with miR-138 relative to site 1. These
results indicate that miR-138 can bind to its target sites on
ICP0 mRNA in HSV-infected cells.
miR-138 Downregulates Lytic Gene Expression in HSV-
1-Infected Cells
As an initial test of whether miR-138 can affect lytic gene expres-
sion in HSV-1-infected cells, we transfected 293T cells with a
miR-138 mimic together with either an oligonucleotide inhibitor
complementary to miR-138 or a control scrambled oligonucleo-
tide inhibitor, and infected with HSV-1. We observed higher
expression of ICP0, the L protein gC, and, to a lesser extent,
the IE protein ICP4, in the presence of the miR-138 inhibitor
than with the control oligonucleotide (Figure 3A).
To investigate further, we used bacterial artificial chromosome
(BAC) technology to generate a mutant virus (M138) expressing
ICP0 mRNA with the aforementioned M138 mutations in the 30
UTR in the background of WT HSV-1 strain KOS (Figure 1C). To
ensure that differences between WT and M138 are due to the
engineered mutations, we also generated a rescued derivative
(R138), in which WT ICP0 sequences were restored. The M138
mutations do not change ICP0 protein coding sequences. They
are located within sequences encoding the stable LAT intron,
but500 bp away from the splicing branchpoint (Krummenacher
et al., 1997), and do not affect expression of stable LATs (see
below). Because there are two copies of the ICP0 gene in the
HSV-1 genome, mutations were introduced into the BACs using
two different drug resistance genes as selection markers and
two-step Red-mediated recombination (Figures S2A and S2B).
Figure 3. miR-138 Downregulates Viral Gene Expression in HSV-1-Infected Cells
(A) 293T cells were transfected with miR-138mimic together with either a complementary oligonucleotide inhibitor or a control inhibitor before being infected with
WT HSV-1 at an moi of 0.1 and harvested at 48 hpi.
(B and C) Vero (B) and Neuro-2A (C) cells were mock infected (Mock) or infected with the indicated viruses at an moi of 10 and harvested at the times shown. In all
three panels, protein expression was analyzed by western blot. The proteins analyzed are indicated to the left of the panels with actin serving as a loading control.
See also Figure S2.
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Host miRNA Promotes HSV-1 LatencyWT, M138, and R138 viruses replicated with similar kinetics in
Vero cells and in Neuro-2A cells (Figure S2C). Following infection
at an moi of 10, expression of ICP0 was similar for all three
viruses in Vero cells (Figure 3B), where miR-138 is poorly ex-
pressed (Figure 1A). However, in infected Neuro-2A cells where
miR-138 is abundantly expressed (Figure 1A), the M138 muta-
tions increased the expression of ICP0 between 2- and 4-fold,
the IE protein ICP27, and the L protein gC 2-fold, and the
expression of the IE protein ICP4 and the E protein TK, but
less than 2-fold, at 7 and 12 hr postinfection (hpi) (Figures 3C
and S2D). We observed similar levels of ICP4 in cells infected
with the three viruses at 3 hpi, indicating that the cells were
equally infected. At an moi of 0.5, the M138 mutations also
increased ICP0 levels at 24 hpi (data not shown).
As an additional test, we transfected the miR-138 mimic or the
mutant miR-M138 mimic (Figure 1C) into 293T cells where
endogenous miR-138 levels are low (Figure 1A), and infected
the cells with either WT or M138 virus 8 hr posttransfection at
a low moi. Notably, the miR-M138 mimic contains three nucleo-
tide changes that compensate for the changes in ICP0mRNA in
the M138 virus. Transfection of the miR-138 mimic reduced
levels of ICP0 in WT-infected cells relative to transfection of
the mutant mimic, miR-M138, whereas transfection of miR-
M138 reduced levels of ICP0 inM138 virus-infected cells relative
to transfection of miR-138, particularly at 48 hpi (Figure S2E).
These results taken together indicate that high levels of
endogenous or introduced miR-138 downregulate lytic viral
gene expression in cells infected with HSV-1, dependent on
miR-138 target sites in ICP0 mRNA.
TheM138Mutations Increase Expression of Lytic Genes
during Establishment of Latency
We next investigated whether miR-138 repression of ICP0
expression affects lytic gene expression during establishment
of latency in mouse TG. Mice were inoculated on the cornea
with WT or M138, and virus replication was assessed at that
site by titrating eye swabs on 1, 3, 5, and 7 days postinfection
(dpi), and in the TG by titrating ganglionic homogenates at 3, 5,
and 7 dpi. The M138 mutant exhibited WT eye swab and gangli-Cellonic titers (Figures 4A and 4B). Eye swab titers decreased from 1
to 3 dpi but increased from 3 to 5 dpi, which might suggest rein-
fection of the cornea from the TG, before decreasing again to
very low levels at 7 dpi. TG titers decreased from 3 dpi to very
low levels at 7 dpi (Figure 4B), suggesting that at 7 dpi acute
ganglionic replication is waning and latency is being established.
Eye swab and ganglionic titers were also similar between M138-
and R138-infected mice (data not shown).
Next we analyzed TG samples obtained at 7 dpi from mice
infected with WT, M138, or R138 for viral DNA levels by qPCR,
and RNA levels by qRT-PCR. The M138 mutations had little or
no effect on viral genome levels or levels of the stable LAT intron
(Figure 4C). However, they significantly increased the levels of
ICP0 transcripts (Figure 4C). Considering ICP0’s role in acti-
vating lytic genes, we also analyzed the levels of other lytic tran-
scripts, namely ICP4 (IE), ICP27 (IE), tk (E), and gC (L). The M138
mutations increased levels of all four of these lytic transcripts by
about 3-fold (2.3- to 3.8-fold; Figure 4C), and all of these differ-
ences were statistically significant (p < 0.05), except the differ-
ence between the ICP4 levels of WT and M138 (p = 0.06). There
were no significant differences in transcript levels in ganglia
infected with WT versus R138 viruses (Figure 4C), indicating
that the increases in transcript levels in M138-infected mice
were due to the engineered mutations. We performed an inde-
pendent replicate of this experiment, which yielded very similar
results (Figure S3). We also found that ICP0 transcript levels
were significantly correlated with levels of each of the other lytic
transcripts assayed, but not with LATs, consistent with previous
studies suggesting divergent pathways for acute and latent in-
fections (Margolis et al., 1992; Speck and Simmons, 1991).
Notably, the correlation between ICP0 and the other lytic tran-
scripts was increased by the M138 mutations (Figure 4D; Table
S1). Taken together, the results show that the miR-138 target
site mutations in ICP0 mRNA increase lytic gene expression
during establishment of latency in mouse TG.
The M138 Mutations Increase Morbidity and Mortality
Infection of CD-1mice by HSV-1 strain KOS usually results in low
mortality and thus efficient establishment of latency (Leib et al.,Host & Microbe 15, 446–456, April 9, 2014 ª2014 Elsevier Inc. 449
Figure 4. Virus Replication and Gene Expression during Acute Infection of Mice
(A) Virus replication in the eye. Each point represents the geometric mean titer of at least 15 eye swabs.
(B) Virus replication in the TG. Each point represents the geometric mean titer of at least 10 TG. There are no statistically significant differences between the titers
of WT and M138 viruses in (A) and (B).
(C) Viral genome and transcript levels in TG at 7 dpi. Each point represents a value from one TG. Virus names are shown at the bottom, and themolecules assayed
are labeled at the top of each graph. Vertical axes show logarithmic values, and RNA levels were normalized to viral genome levels. The horizontal lines represent
the geometric means (any undetectable values were included in the calculations of means as logs of the detection limits). p values for the two viruses compared
are shown on top of the brackets.
(D) Correlations between transcript levels in TG infected by the viruses indicated at the top of each plot at 7 dpi. The levels of gC transcripts or LATs were plotted
against the level of ICP0 transcripts in the same TG. One TG that exhibited undetectable levels of gC and ICP0 transcripts was excluded from the plots. R2 and p
values for each correlation are shown at the upper left corners of the plots. See also Figure S3 and Table S1.
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Figure 5. The M138 Mutant Virus Causes Increased Mortality and Disease
(A) Survival curves of mice infected by the viruses indicated in the key. Percentages of live mice as a function of time were plotted. The numbers of mice studied
and the p values for the differences between viruses are shown below the curves.
(B) Mice showing encephalitis symptoms. The bars represent percentages of mice at 17 or 25 dpi that showed impaired mobility, i.e., partial paralysis or lethargy.
The viruses and the numbers of mice studied for each virus are indicated to the right of the graph. p values for statistical comparisons are shown above the
brackets, and those with statistical significance are labeled with asterisks below the brackets. Since two Fisher’s exact tests were performed for each time point,
the threshold alpha level below which a p value is considered significant is adjusted from 0.05 to 0.0253 in order to control for multiple comparisons.
(C) Titers of WT and M138 viruses in mouse brain at 7 dpi. Each point represents a value from one brain. The horizontal lines represent the geometric means of
titers. See also Figure S4.
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and mortality, we followed infected mice for 32 days in each of
the two replicate experiments. Pooling the data from the two
experiments, the percentage of mice infected with M138 that
died (or in one case became moribund and was euthanized)
was nearly four times higher than that for WT or R138 (28%
versus 7.7% or 7.5%; Figures 5A and S4A). The differences in
survival were statistically significant, with p values of 0.019 and
0.016, respectively. Most deaths occurred between 9 and 13
dpi (Figure 5A). At 17 and 25 dpi, the surviving mice were
observed for partial paralysis or lethargy (impaired mobility),
which are sequelae of HSV encephalitis. A higher percentage
of mice infected with M138 showed impaired mobility than did
those infected with WT or R138 (Figure 5B). To determine
whether the increased morbidity and mortality were due to
increased spread to the CNS, we measured viral titers in the
brain, and found no significant difference between mice infected
with WT and M138 (Figure 5C). Interestingly, when M138 was
delivered to the brain by a different route—intracranial inocula-
tion—it caused little if any increase in mortality relative to R138
(Figure S4B; see Discussion). Regardless, these results indicate
that following corneal inoculation, the miR-138 target site
mutations increase morbidity and mortality, and thus decrease
survival and latency.
Effects of M138 Mutations on Gene Expression during
Maintenance of Latency
To study whether miR-138 repression of ICP0 regulates viral
gene expression during maintenance of latency, TG were har-
vested frommice infectedwithWT,M138, or R138 at 32 dpi. Viral
genome levels were analyzed by qPCR, and levels of the stable
LAT intron and the lytic ICP0, ICP27, tk, and gC transcripts were
analyzed by qRT-PCR. Genome and LAT intron levels were very
similar for the three viruses (Figure 6A). Lytic transcript levels
were, as expected (Kramer and Coen, 1995), low and detectable
in only 30%–70% of TG for any given transcript (Figure 6A).
Making the assumption that ganglia in which a transcript was
undetectable meant that there was no expression of that tran-
script, then the M138 mutant expressed more lytic transcriptsCellon average for all four genes analyzed than did the WT and
R138 viruses (data not shown). However, these differences
were not statistically significant. Nevertheless, all four lytic tran-
scripts were detectable in a higher fraction of M138-infected TG
than in WT- or R138-infected TG (Figure 6A). A separate exper-
iment performed with fewer mice but using identical conditions
also resulted in a higher fraction of M138-infected TG having
detectable ICP0 and ICP27 transcripts than WT- and R138-
infected TG (data not shown). Pooling the data from the two
experiments, M138 infection was associated with increased
fractions of TG exhibiting detectable transcripts for all four lytic
genes, with the increases being statistically significant for
ICP27 (Figure 6B). Analyzing only those TG in which both tran-
scripts could be detected, ICP0 levels were uncorrelated with
LAT levels, but were significantly correlated with the levels of
the other three lytic transcripts in M138-infected TG (Figure 6C).
These data suggest that the miR-138 target site mutations may
also increase expression of lytic genes during maintenance of
latency.
DISCUSSION
The mechanisms that promote HSV-1 latency have remained
largely obscure, although roles for neuronal factors and for
repression of ICP0, which is important for antagonizing host
silencing mechanisms and for efficient replication and reactiva-
tion in ganglia, have long been suspected (reviewed in Roizman
et al., 2013; Boutell and Everett, 2013). Here we found that a
neuron-specific host miRNA, miR-138, binds to two target sites
in ICP0 mRNA and can repress ICP0 expression in both trans-
fected and HSV-1-infected cells. This repression is dependent
on the miR-138 seed sequence and its target sites in ICP0
mRNA. Importantly, mutations of these miR-138 target sites do
not affect ICP0 expression in cells in which miR-138 is not abun-
dant. However, in cells into which exogenous miR-138 is intro-
duced, and in Neuro-2A cells and in mouse TG tissue where
endogenous miR-138 is abundant, these mutations result in
increased expression of ICP0 and other lytic genes. By far the
simplest interpretation of these results is that high levels ofHost & Microbe 15, 446–456, April 9, 2014 ª2014 Elsevier Inc. 451
Figure 6. Viral Genome Levels and Gene Expression during Latent Infection of Mice
(A) Viral genome and transcript levels at 32 dpi. Values are presented as in Figure 4C, except that mean values are not indicated in the plots for viral lytic
transcripts, because the large numbers of undetectable values make difficult meaningful calculations of means.
(B) Percentages of TG exhibiting detectable lytic transcripts. Each vertical bar represents the value for each virus (indicated in the key) and each RNA (below the
graph). Since two Fisher’s exact tests were performed for each gene, the threshold alpha level below which a p value is considered significant is adjusted from
0.05 to 0.0253 in order to control for multiple comparisons. Therefore, only p values below 0.0253 have been displayed.
(C) Correlation between transcript levels in M138 virus infected TG at 32 dpi. The plots are presented as in Figure 4D. Only TG exhibiting detectable transcripts for
both RNAs being compared are included in the analysis.
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Host miRNA Promotes HSV-1 LatencymiR-138 ordinarily repress ICP0 expression in infected neurons,
which, given ICP0’s role as a viral transactivator, results in
reduced lytic gene expression. As repression of lytic gene
expression is a hallmark of HSV latency, miR-138 targeting of
ICP0 expression in infected TG promotes latency. Moreover,
the miR-138 target site mutations in ICP0 increase host
morbidity and mortality. As host survival is a crucial prerequisite
for latency, miR-138 targeting of ICP0 expression also promotes
latency by preventing the death of the host.
Thus, miR-138 is a neuronal factor that contributes to HSV-1
latency. We speculate that HSV-1 has evolved to utilize this
hostmiRNA to gain the selective advantage of increased latency,
which in turn increases the ability of the virus to spread
throughout the population. Consistent with this speculation,452 Cell Host & Microbe 15, 446–456, April 9, 2014 ª2014 Elsevier InHSV-2 ICP0 mRNA also contains a predicted miR-138 target
site with full seed complementarity in its 30 UTR, although we
caution that there is only one such site and it is less complemen-
tary overall to miR-138 than is either of the HSV-1 ICP0 target
sites. It is also possible that miR-138 targets viral (and host)
genes other than ICP0 to promote latency.
We found more obvious effects of miR-138 targeting of ICP0
on lytic gene expression during establishment of latency (7 dpi)
than during maintenance (32 dpi). This may be due, at least in
part, to our assays of gene expression at 32 dpi not being sensi-
tive enough to detect lytic transcripts in a substantial fraction of
samples. Alternatively, it is possible that by 32 dpi, mechanisms
other than miR-138 targeting of ICP0, such as chromatin-
mediated effects (reviewed in Knipe and Cliffe, 2008), are morec.
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levels of ICP0 transcripts were still positively correlated with
those of other lytic transcripts, at least in TG latently infected
with M138, consistent with ICP0 being able to activate expres-
sion of these other viral genes during latency. Although the
M138mutations do not appear to affect reactivation of infectious
virus following explant of TG (our unpublished data), and
although abundant activation of ICP0 expression by a reactiva-
tion stimulus may overcome any miR-138 repression, it is never-
theless possible that the M138 mutations could affect gene
expression during this phase of infection. This possibility is under
investigation.
Although there is evidence that miRNAs encoded by herpesvi-
ruses including HSVmay promote latency by repressing expres-
sion of key lytic genes (reviewed in Cullen, 2011), and there are
examples of host miRNAs that modulate virus production in
herpesviruses (Nachmani et al., 2010; Yin et al., 2008), hepatitis
C virus (Jopling et al., 2005), and human papillomaviruses (Guna-
sekharan and Laimins, 2013), here we show that miR-138 is
a host miRNA that promotes herpesvirus latency by directly
repressing lytic gene expression. We suspect that other herpes-
viruses may utilize host miRNAs that are abundant in the cell
types in which they form latent infections to repress lytic gene
expression. A recent paper describes one possible case in which
oligonucleotide inhibitors of either of two host miRNAs increased
lytic gene expression and virus production in cells that were
latently infected with Kaposi’s sarcoma herpesvirus (KSHV)
and stimulated with a phorbol ester (Yan et al., 2013). This study
also provided evidence from reporter gene assays that these
host miRNAs target a KSHV IE gene, but did not examine unsti-
mulated cells and did not examine a viral mutant. Interestingly, it
has been reported that HIV-1 contains binding sites for several
host miRNAs that can repress viral gene expression and reacti-
vation in latently infected resting CD4+ T cells, although a virus
whose binding sites for one or more of these miRNAs were inac-
tivated was not investigated (Huang et al., 2007).
A key question remaining is what accounts for the role of miR-
138 targeting of ICP0 in suppressing viral virulence. Our data
argue against the miR-138 target site mutations causing
increased spread of virus to the brain to cause encephalitis
and death. Although we cannot rule out that we missed an
increase in infectious virus due to choice of time points, the
mutations also did not result in increased virus production in
cell culture or in TG. Perhaps WT levels of ICP0 are sufficient
for maximal virus production, or perhaps the increase in ICP0
expression occurs too late during the infectious cycle to affect
virus production. Regardless, we raise the possibility that over-
expression of ICP0 and/or other lytic genes without increased
virus production results in increased virulence following corneal
inoculation. One possible mechanism, consistent with increased
virulence following corneal but not intracranial inoculation, is that
increased viral gene expression results in increased pathology
due to adaptive immune responses. Another possible mecha-
nism stems from the role of ICP0 in combating innate immunity
(Melroe et al., 2004; Mossman et al., 2000; Orzalli et al., 2012;
Paladino et al., 2010). Perhaps increased expression of ICP0
results in more inhibition of innate immunity in the brain following
spread of virus from the TG. Consistent with this possibility,
impaired innate immune signaling has been associated withCellincreased susceptibility to HSV encephalitis in humans (Lafaille
et al., 2012).
In summary, we have identified a molecular mechanism by
which host neurons provide an environment that promotes
HSV latency. We emphasize that as the M138 mutant is still
able to establish and maintain latency, this mechanism is just
one of likelymany that contribute to latent infection. It is possible,
for example, that miR-138 acts synergistically with virus-
encoded miRNAs such as miR-H2 that target ICP0. Another
interesting possibility is that expression of miR-138may be regu-
lated differentially during lytic infection and the various phases of
latent infection (or even in different neuron subtypes), especially
as the tissue-specific expression of this miRNA appears to be
posttranscriptionally controlled (Obernosterer et al., 2006). It
will be important to identify the various mechanisms that
contribute to latent infection and to understand how they interact
in repressing lytic gene expression and ensuring host survival.
EXPERIMENTAL PROCEDURES
Cells and Viruses
Vero, 293T, and HFF cells were maintained as previously described (Pan and
Coen, 2012a; Jurak et al., 2012). 293 and Neuro-2A cells (ATCC) were main-
tained in DMEM supplemented with 10% fetal bovine serum at 37C in 5%
CO2. BAC-derived HSV-1 strain KOS (Jurak et al., 2012) and M138 and
R138 (see below) were used for all experiments except the PAR-CLIP assay,
which used HSV-1 strain 17syn+. Infectious virus was harvested from cell
cultures and TG and titrated as described previously (Leib et al., 1989). The
derivation of M138 and R138 using BAC technology is outlined in Figure S2A
and described in detail in Supplemental Experimental Procedures.
Quantitative PCR and RT-PCR
For miRNA quantification, total RNA from cells or tissues was purified using
RNeasy mini kit (QIAGEN). RNA from primary neuron cultures isolated from
rat SCG was a generous gift from Angus Wilson and Michael O’Brien (New
York University). miR-138 and snRNA U6 levels were evaluated using 10 ng
of total RNA and TaqMan microRNA assays (Applied Biosystems) according
to the manufacturer’s instructions. Previous qPCR or qRT-PCR assays for
HSV-1 genome and transcripts of ICP0, tk, the LAT intron, and mouseGAPDH
(Chen et al., 2002; Kramer et al., 2011; Pesola et al., 2005) were modified and
optimized, and new assays were developed for ICP4, ICP27, gC, and human
GAPDH. Details are provided in Supplemental Experimental Procedures.
DNA Constructs
The ICP0-WT plasmid (pRS-1) was a generous gift of Rozanne Sandri-Goldin
(Sandri-Goldin et al., 1987). This plasmid includes the entire ICP0 gene, with its
promoter, cloned into pUC-18. The ICP0-M138 plasmid was created using a
QuikChange Site-Directed Mutagenesis Kit (Agilent) following the manufac-
turer’s protocol. The seed sequence for both predicted miR-138 binding sites
was changed from 50-ACACCAGC-30 to 50-ACAGCTGA-30. The pre-miR-138
stem loop was PCR amplified from human genomic DNA derived from SH-
SY5Y cells, together with 200 bp of the 50 and 30 flanking regions, and cloned
into pcDNA3 to generate pcDNA-miR138 for cotransfection assays. The same
region of human DNA was also cloned into the pLEX lentiviral vector for pro-
duction of lentiviral particles by transfection of 293 cells. Sequences of primers
used are provided in Supplemental Experimental Procedures.
PAR-CLIP Library Construction and Bioinformatics
293 cells were transduced with either the control, parental pLEX lentiviral vec-
tor (OpenBiosystems) lacking an inserted pri-miRNA sequence, or the same
vector containing the pri-miR-138 sequence described above, and transduc-
tants selected using puromycin. The selected cells were pulsed with 4SU 16 hr
prior to infection, then infected with HSV-1 at an moi of 2 for 4 hr, UV cross-
linked, and collected for PAR-CLIP. The PAR-CLIP library was constructed
as described previously (Hafner et al., 2010) with minor modifications; i.e.,Host & Microbe 15, 446–456, April 9, 2014 ª2014 Elsevier Inc. 453
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Illumina HiSeq 2000 was used for sequencing. Resulting reads were then pro-
cessed using the FASTX-toolkit and aligned to the HSV-1 genome using Bow-
tie (Langmead et al., 2009). Reads of at least 15 nt in length, with minimum 50
reads total, were retained if they mapped to HSV-1 with%2 mismatches.
Transfection
For cotransfection using a miR-138 mimic, 293T cells in each well of a 24-well
plate were cotransfected with 75 ng of ICP0 (WT) plasmid and 4 pmol of
miScript miR-138 or miR-M138 mimic (QIAGEN). Cells were harvested at
24 hpi. For cotransfection using a miR-138 expression plasmid, 293T cells in
each well of a 6-well plate were cotransfected with 0.5 mg of ICP0 (WT or
M138) plasmid and 2.5 mg of pcDNA-miR138, with an additional 1 mg of GFP
expression plasmid, which served as a transfection and loading control. Cells
were harvested at 48 hr posttransfection. For transfection-infection, 293T cells
in each well of a 24-well plate were transfected with 8 pmol of the miR-138 or
miR-M138 mimic with or without 16 pmol of miScript miR-138 inhibitor or a
control scrambled inhibitor (QIAGEN). After 8 hr, the cells were infected with
virus at an moi of 0.1 and lysed for analysis at 48 hpi. All transfection proce-
dures used Lipofectamine 2000 (Invitrogen) according to the manufacturer’s
protocol.
Western Blotting
Western blots were performed as previously described (Pan and Coen,
2012b). The following antibodies and dilutions were used for probing the blots:
ICP0 mouse monoclonal antibody (Virusys), 1:8000; GFP monoclonal (Santa
Cruz), 1:20,000; ICP4 mouse monoclonal (Abcam), 1:1000; ICP27 mouse
monoclonal (Virusys), 1:1000; TK mouse monoclonal (a generous gift from
Bill Summers, Yale University), 1:1000; gC mouse monoclonal (Fitzgerald),
1:1000; actin antibody (Sigma), 1:10,000; and HRP-conjugated goat anti-
mouse antiserum (SouthernBiotech), 1:2000. Images were visualized by either
using a Syngene G:Box gel imaging system or film.
Animal Procedures
Animal housing and experimental procedures were approved by the Institu-
tional Animal Care and Use Committee of Harvard Medical School in accor-
dance with federal guidelines. Male CD-1 mice (Charles River Laboratories)
were anesthetized by intraperitoneal injection of 100 mg/kg ketamine (Fort
Dodge Animal Health) and 10 mg/kg xylazine (Lloyd Laboratories). 2 3 105
pfu of virus in 3 ml was dropped onto each scarified cornea of 7-week-old
mice. For eye swab collection, mice were anesthetized transiently in an induc-
tion chamber with isoflurane (3% in oxygen 0.5 ml/min) using an anesthesia
machine (Colonial Medical Supply). Both eyes of each mouse were swabbed
with cotton-tipped applicators, which were suspended in 1 ml of cell culture
media. For TG or brain acquisition, mice were sacrificed by cervical dislocation
while under inhalation anesthesia with isoflurane as above, and the TG or brain
was rapidly removed and placed on dry ice before storing at 80C. TG and
brain were homogenized in cell culture media for titers. Mice were observed
daily, and mortality figures include mice that had died and one that was mori-
bund and therefore euthanized. At 17 and 25 dpi each mouse was scored for
its mobility (partial paralysis or lethargy). All of these mice were recovering by
32 dpi.
Statistical Analysis
Statistical analysis was performed using Prism 6 (GraphPad). Titers and DNA
and RNA levels were analyzed by Kruskal-Wallis tests for all virus genotypes,
along with Dunn’s post tests for M138 versus WT and M138 versus R138
(controlling for multiple comparisons). Survival curves were analyzed by the
log rank (Mantel-Cox) test. The number of mice with encephalitis sequelae
at 17 and 25 dpi or of TG with detectable transcripts at 32 dpi was analyzed
by Fisher’s exact test. The covariance of transcript levels was evaluated using
Pearson correlations.
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